Werewolf Therapeutics (HOWL) Share-based Compensation (2020 - 2026)
Werewolf Therapeutics (HOWL) posted quarterly Share-based Compensation of $419000.0 for Q2 2026, down 76.63% year-over-year from $1.8 million in Q2 2025, and down 54.9% on a QoQ basis from $929000.0 in Q1 2026.
Werewolf Therapeutics (HOWL) Share-based Compensation (2020 - 2026) Analysis & Trends
Werewolf Therapeutics has reported Share-based Compensation for 7 years, with the latest figure at $419000.0 in Q2 2026.
- Share-based Compensation for Q2 2026 came in at $419000.0, down 76.63% year-over-year; the trailing twelve-month figure through Jun 2026 was $3.8 million (down 50.84% YoY), and the FY2025 annual result was $6.2 million, down 29.24% from the prior year.
- Share-based Compensation slipped to $419000.0 in Q2 2026, from $929000.0 in the prior quarter.
- Over five years, Share-based Compensation peaked at $2.6 million in Q2 2024 and troughed at $419000.0 in Q2 2026.
- A 5-year average of $1.8 million and a median of $1.9 million in 2023 frame the typical range for Share-based Compensation.
- The largest YoY upside for Share-based Compensation was 223.75% in 2022 against a maximum downside of 82.12% in 2022.
- A 5-year view of Share-based Compensation shows it stood at $1.9 million in 2022, then retreated by 3.55% to $1.9 million in 2023, then advanced by 1.87% to $1.9 million in 2024, then slumped by 36.43% to $1.2 million in 2025, then tumbled by 65.46% to $419000.0 in 2026.
- Per Business Quant data, the three most recent Share-based Compensation figures were $419000.0 in Q2 2026, $929000.0 in Q1 2026, and $1.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Werewolf Therapeutics | 20.90 Mn | 20.90 Mn | - | 419,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 419,000.00 |
| Jun 30, 2026 | 419,000.00 |
| Mar 31, 2026 | 929,000.00 |
| Mar 31, 2026 | 929,000.00 |
| Dec 31, 2025 | 1.21 Mn |
| Dec 31, 2025 | 1.21 Mn |
| Sep 30, 2025 | 1.23 Mn |
| Sep 30, 2025 | 1.23 Mn |
| Jun 30, 2025 | 1.79 Mn |
| Jun 30, 2025 | 1.79 Mn |
| Mar 31, 2025 | 2.01 Mn |
| Mar 31, 2025 | 2.01 Mn |
| Dec 31, 2024 | 1.91 Mn |
| Dec 31, 2024 | 1.91 Mn |
| Sep 30, 2024 | 2.01 Mn |
| Sep 30, 2024 | 2.01 Mn |
| Jun 30, 2024 | 2.60 Mn |
| Jun 30, 2024 | 2.60 Mn |
| Mar 31, 2024 | 2.31 Mn |
| Mar 31, 2024 | 2.31 Mn |